This study revealed that 20-30 percent of TB patients who were taking antituberculosis therapy developed elevated liver function tests. Half of the elevation in liver enzyme values occurred within the first two months of treatment. No statistically significant differences between sex, race and liver toxicity was found in this study. The time from initiation of treatment for TB to development of hepatotoxicity was shorter for females and whites. Physicians and public health workers should monitor the liver function tests of TB patients who are taking antituberculosis treatment. Recommendations for monitoring hepatotoxicity vary depending on the age of the patients. For patients less than 35 years old, monthly symptom review for jaundice, acholic stools, fever, anorexia, nausea and vomiting, may be adequate. For older patients, liver function tests are recommended monthly or every one to two months.